Skip to main content

Isis, Roche Partner on Huntington’s Disease Drug Program


Isis Pharmaceuticals this week announced that it has formed an alliance with Roche to develop antisense-based treatments for Huntington’s disease.

The companies are also working together to combine Isis’ antisense oligos with Roche’s so-called brain shuttle program to increase the brain penetration of the molecules with systemic administration, Isis said.

Roche will pay Isis $30 million upfront, and Isis stands to receive up to $362 million in license fees and milestone payments. Isis will also be entitled to tiered royalties on sales of any drug resulting from the alliance.

Isis will be responsible for drug development up until the completion of phase I testing. Roche has the option to license any drug after phase I, at which point it will be responsible for all further development and commercialization responsibilities.

Additional terms of the deal were not disclosed.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.